What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations — branded generics, active pharmaceutical ingredients (APIs) and contract research/analytical services — across domestic and international markets from 10 manufacturing facilities with US FDA, UK-MHRA and EU GMP approvals. In FY26, consolidated revenue was ₹1,845.32 crore. The Indian domestic formulations business sells through a field force covering 2.42 lakh prescribing doctors (IQVIA rank 33), with the top brand Cyclopam at ₹196 crore and the top five brands making up 42% of domestic portfolio revenue. International formulations — sold into the US, Europe and emerging markets — contributed 35% of revenue at ₹1,451 million in Q1 FY27 and surged 94.6% YoY in Q4 FY26 to ₹2,147 million, with US business up 77.5% in that quarter. The API business, aimed at backward integration, grew 42% YoY to ₹522 million in Q1 FY27. Contract research and analytical services revenue rose 65.3% in Q4 FY26 to ₹895 million. The Ophthalmic Division (India plus 15-16 African countries) was divested to Sunways on a slump sale basis completed in May 2026. Major costs are materials (23.1% of FY26 revenue), employees (23.1%) and other operating expenses (39.9%); depreciation was 6.9% and FY26 capex 8.0% of revenue. The company carries ₹930-960 crore of debt with a stated annual repayment commitment of around ₹140 crore.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from INDOCO REMEDIES LTD.'s filed financials and exchange disclosures
INDOCO REMEDIES LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol INDOCO.
Yes. Over the trailing twelve months INDOCO REMEDIES LTD. reported a net profit of ₹3 Cr on revenue of ₹1,873 Cr.
Yes. The dividend yield is 0.08% at the current price.
No. Debt stands at 1.11× equity, and it carries net debt of ₹1,010 Cr. That is lower than 5% of its 171 Pharmaceuticals peers.
On trailing P/E, INDOCO REMEDIES LTD. ranks 169 of 169 in Pharmaceuticals — cheaper than 0% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session INDOCO REMEDIES LTD. moves 1.52% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by INDOCO REMEDIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
